Marshall Wace’s CME Group CME Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $238M | Buy |
804,218
+789,933
| +5,530% | +$235M | 0.24% | 59 |
|
|
2025
Q4 | $3.9M | Sell |
14,285
-89,065
| -86% | -$24.2M | ﹤0.01% | 1268 |
|
|
2025
Q3 | $27.9M | Buy |
103,350
+99,658
| +2,699% | +$27.1M | 0.03% | 517 |
|
|
2025
Q2 | $1.02M | Sell |
3,692
-28,293
| -88% | -$7.69M | ﹤0.01% | 1840 |
|
|
2025
Q1 | $8.49M | Sell |
31,985
-59,526
| -65% | -$14.7M | 0.01% | 834 |
|
|
2024
Q4 | $21.3M | Buy |
+91,511
| New | +$21M | 0.03% | 521 |
|
|
2024
Q3 | – | Sell |
-232,200
| Closed | -$45.7M | – | 2561 |
|
|
2024
Q2 | $45.7M | Buy |
+232,200
| New | +$48M | 0.06% | 284 |
|
|
2024
Q1 | – | Sell |
-1,400
| Closed | -$295K | – | 2481 |
|
|
2023
Q4 | $295K | Buy |
+1,400
| New | +$299K | ﹤0.01% | 1894 |
|
|
2023
Q2 | – | Sell |
-30,240
| Closed | -$5.79M | – | 2524 |
|
|
2023
Q1 | $5.79M | Buy |
+30,240
| New | +$5.47M | 0.01% | 924 |
|
|
2022
Q3 | – | Sell |
-202,452
| Closed | -$41.4M | – | 3391 |
|
|
2022
Q2 | $41.4M | Buy |
202,452
+107,888
| +114% | +$22.9M | 0.09% | 248 |
|
|
2022
Q1 | $22.5M | Buy |
94,564
+77,704
| +461% | +$18.2M | 0.04% | 452 |
|
|
2021
Q4 | $3.85M | Sell |
16,860
-2,322
| -12% | -$511K | 0.01% | 1569 |
|
|
2021
Q3 | $3.71M | Buy |
+19,182
| New | +$3.89M | 0.02% | 1138 |
|
|
2020
Q2 | – | Sell |
-978
| Closed | -$169K | – | 1596 |
|
|
2020
Q1 | $169K | Buy |
+978
| New | +$195K | ﹤0.01% | 1211 |
|
|
2019
Q4 | – | Sell |
-4,386
| Closed | -$927K | – | 1738 |
|
|
2019
Q3 | $927K | Sell |
4,386
-13,667
| -76% | -$2.86M | 0.01% | 962 |
|
|
2019
Q2 | $3.5M | Sell |
18,053
-34,016
| -65% | -$6.27M | 0.03% | 599 |
|
|
2019
Q1 | $8.57M | Buy |
52,069
+35,306
| +211% | +$6.24M | 0.08% | 306 |
|
|
2018
Q4 | $3.15M | Buy |
16,763
+10,947
| +188% | +$2.02M | 0.03% | 607 |
|
|
2018
Q3 | $990K | Buy |
+5,816
| New | +$979K | 0.01% | 812 |
|
|
2018
Q2 | – | Sell |
-99,902
| Closed | -$16.2M | – | 720 |
|
|
2018
Q1 | $16.2M | Buy |
+99,902
| New | +$15.9M | 0.67% | 41 |
|
|
2017
Q4 | – | Sell |
-92,005
| Closed | -$12.5M | – | 413 |
|
|
2017
Q3 | $12.5M | Buy |
92,005
+88,872
| +2,837% | +$11.2M | 0.58% | 41 |
|
|
2017
Q2 | $392K | Buy |
+3,133
| New | +$375K | 0.02% | 262 |
|
|
2017
Q1 | – | Sell |
-44,976
| Closed | -$5.19M | – | 379 |
|
|
2016
Q4 | $5.19M | Buy |
44,976
+14,634
| +48% | +$1.63M | 0.03% | 462 |
|
|
2016
Q3 | $3.17M | Sell |
30,342
-235,734
| -89% | -$24.6M | 0.02% | 504 |
|
|
2016
Q2 | $25.9M | Buy |
266,076
+110,525
| +71% | +$10.4M | 0.22% | 114 |
|
|
2016
Q1 | $14.9M | Buy |
155,551
+128,427
| +473% | +$11.7M | 0.14% | 156 |
|
|
2015
Q4 | $2.46M | Sell |
27,124
-164,011
| -86% | -$15.4M | 0.02% | 520 |
|
|
2015
Q3 | $17.7M | Buy |
191,135
+177,810
| +1,334% | +$16.9M | 0.22% | 116 |
|
|
2015
Q2 | $1.24M | Buy |
+13,325
| New | +$1.24M | 0.02% | 561 |
|
|
2014
Q4 | – | Sell |
-213,533
| Closed | -$17.1M | – | 834 |
|
|
2014
Q3 | $17.1M | Buy |
213,533
+211,537
| +10,598% | +$15.9M | 0.25% | 124 |
|
|
2014
Q2 | $142K | Buy |
+1,996
| New | +$140K | ﹤0.01% | 883 |
|
Other funds holding CME
VCM
VPM
Marshall Wace's CME Position: Q1 2026 in Review
Marshall Wace increased its CME Group (CME) stake by 5,530% in Q1 2026, buying an estimated $235M and bringing the position to 804,218 shares worth $238M. The position accounts for 0.24% of the portfolio, ranked #59.
Marshall Wace first reported a position in CME in Q2 2014 and has held it in 31 quarters since. 1,790 funds tracked by Wall St. Rank hold CME as of Q1 2026.
- Marshall Wace held 804,218 shares of CME Group worth $238M as of Q1 2026.
- Marshall Wace bought 789,933 CME Group shares in Q1 2026, an estimated $235M.
- CME Group made up 0.24% of Marshall Wace's portfolio in Q1 2026, its #59 holding.
- Marshall Wace first reported a position in CME Group in Q2 2014 and has held it in 31 quarters since.
- 1,790 funds tracked by Wall St. Rank held CME Group as of Q1 2026.
Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.